Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Oct 04, 2023 8:28am
78 Views
Post# 35668514

RE:RE:RE:RE:ICDR

RE:RE:RE:RE:ICDRMost arbitrations  of this type indicate they are  final  and  binding  but  I  do believe that they can be appealed to the courts if the arbitrator erred in  the decision making  process.  Usually  that is why  awards  are many pages  long rather than saying  Party A  wins.

However,  usually  as I  noted  , the issue is with the process and if all the facts were properly considered.   The actual  decision of the arbitrator will likely  not be overturned  on its merits   , usually on  the basis of the process.

So if the arbitrator  makes a finding that seems against the evidence, it might stand  if  proper  consideration was given all the facts.

Teal issue of the appeal is  what it is worth  - if it is actually worth appealing.

In our case  , given that Shiseido has really done all the  work,  to cut and run on them  might not make sense.  Their involvement  may provide continuity  rather than have someone else 'start from scratch'.

But maybe we can get a better deal from them.  Certainly  they have been a big part of the delay  in the whole process.  Maybe with  the  new leadership  on both sides  we can bring this issue around and get progress on bringing the product to market  ASAP!!


GLTA
<< Previous
Bullboard Posts
Next >>